Abstract:Metabolic syndrome (MetS) represents a constellation of metabolic abnormalities, typified by obesity, hypertension, hyperglycemia, and hyperlipidemia. It stems from intricate dysregulations in metabolic pathways governing energy and substrate metabolism. While comprehending the precise etiological mechanisms of MetS remains challenging, evidence underscores the pivotal roles of aberrations in lipid metabolism and insulin resistance (IR) in its pathogenesis. Notably, nicotinamide N-methyltransferase (NNMT) has recently surfaced as a promising therapeutic target for addressing MetS. Single nucleotide variants in the NNMT gene are significantly correlated with disturbances in energy metabolism, obesity, type 2 diabetes (T2D), hyperlipidemia, and hypertension. Elevated NNMT gene expression is notably observed in the liver and white adipose tissue (WAT) of individuals with diabetic mice, obesity, and rats afflicted with MetS. Knockdown of NNMT elicits heightened energy expenditure in adipose and hepatic tissues, mitigates lipid accumulation, and enhances insulin sensitivity. NNMT catalyzes the methylation of nicotinamide (NAM) using S-adenosyl-methionine (SAM) as the donor methyl group, resulting in the formation of S-adenosyl-l-homocysteine (SAH) and methylnicotinamide (MNAM). This enzymatic process results in the depletion of NAM, a precursor of nicotinamide adenine dinucleotide (NAD + ), and the generation of SAH, a precursor of homocysteine (Hcy). Consequently, this cascade leads to reduced NAD + levels and elevated Hcy levels, implicating NNMT in the pathogenesis of MetS. Moreover, experimental studies employing RNA interference (RNAi) strategies and small molecule inhibitors targeting NNMT have underscored its potential as a therapeutic target for preventing or treating MetS-related diseases. Nonetheless, the precise mechanistic underpinnings remain elusive, and as of yet, clinical trials focusing on NNMT have not been documented. Therefore, further investigations are warranted to elucidate the intricate roles of NNMT in MetS and to develop targeted therapeutic interventions.

Structure–Activity Relationship for Small Molecule Inhibitors of Nicotinamide N -Methyltransferase

Identification of novel human nicotinamide N-methyltransferase inhibitors: a structure-based pharmacophore modeling and molecular dynamics approach

Nicotinamide N-methyltransferase Enhances the Capacity of Tumorigenesis Associated with the Promotion of Cell Cycle Progression in Human Colorectal Cancer Cells.

Nicotinamide Phosphoribosyltransferase Inhibitors, Design, Preparation, and Structure–Activity Relationship

Nicotinamide N -methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization

A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders

Synthesis, Biological, and Computational Evaluations of Conformationally Restricted NAD-Mimics as Discriminant Inhibitors of Human NMN-Adenylyltransferase Isozymes

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Comparative Analysis of Two NNMT Bisubstrate Inhibitors through Chemoproteomic Studies: Uncovering the Role of Unconventional SAM Analogue Moiety for Improved Selectivity

Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors

Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy

Drug Discovery Targeting Nicotinamide Phosphoribosyltransferase (NAMPT): Updated Progress and Perspectives

Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome

Molecular Docking‐based Virtual Screening and Dynamics Simulation Study of Novel and Potential SIRT7 Inhibitors

Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors.

Integration of 3D-QSAR, Molecular Docking, and Machine Learning Techniques for Rational Design of Nicotinamide-Based SIRT2 Inhibitors

Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-Yl)anilines Core Identified by Virtual Screening and Biological Evaluation.

Interactions of SIRT1 with Acetyl Substrate, NAD+ or Nicotinamide

Nicotinamide N-methyltransferase (NNMT): A key enzyme in cancer metabolism and therapeutic target

Nicotinamide N-methyltransferase Regulates Hepatic Nutrient Metabolism Through Sirt1 Protein Stabilization

[A Method Based on Endogenous Fluorescence Determination for Screening NAMPT Inhibitors].